Biopharma PEG Scientific Inc.

09/25/2025

💡 AI + Nanomedicine: Unlocking Brain-Targeted mRNA Delivery
A groundbreaking study in ACS Nano presents an AI-validated framework for engineering brain-targeted lipid nanoparticles (BT-LNPs), designed to cross the blood–brain barrier (BBB) and achieve selective neuronal transfection.

🔬 How it works:
The team created a library of BT-LNPs formulated with:
● SM-102 (ionizable lipid, also used in COVID-19 vaccines)
● DOPE & cholesterol
● PEG-lipids (DMG-PEG1000 and DMG-PEG2000)
👉 Importantly, DMG-PEG2000 was conjugated to small molecules (e.g., acetylcholine, glucose, ni****ne), enabling receptor interactions for BBB crossing.
👉 To balance stability and cellular uptake, shorter PEG chains like DMG-PEG1000 were included, reducing steric hindrance and enhancing targeting efficiency.

✨ Key Outcomes:
🟩 Acetylcholine-modified LNPs showed a 3.6-fold increase in brain transfection vs. untargeted LNPs.
🟩 Human iPSC-derived BBB and brain organoid models confirmed successful neuron transfection.
🟩 AI-based predictions aligned with in vivo results, accelerating discovery and reducing animal testing.

This work highlights a scalable, modular platform for precision CNS gene therapies, with enormous potential for treating neurodegenerative diseases.

😄 We are proud that DMG-PEG1000 and DMG-PEG2000, essential PEG-lipids for LNP formulation, are available from Biopharma PEG.

🔗 Learn more: https://www.biochempeg.com/product/mPEG-DMG.html

📖 Full article: https://doi.org/10.1021/acsnano.4c15013

09/22/2025

🚀 ADC Market & Pipeline Update – H1 2025
Antibody-drug conjugates (ADCs) remain one of the fastest-growing areas in oncology.
🔹 As of today, 19 ADCs are approved worldwide.
🔹 In H1 2025, global ADC sales reached ~$8B, with full-year sales expected to surpass $16B.
🔹 Leading products like Enhertu, Padcev, Kadcyla, Polivy, Adcetris, and Trodelvy all reported strong performances.

At the same time, innovation in the pipeline continues:
🔹 200+ clinical-stage ADCs globally, targeting 50+ antigens
🔹 41 ADCs in Phase III, including emerging targets such as HER3, B7-H3, CLDN18.2, ROR1
🔹 Bispecific ADCs (e.g., EGFR/HER3, CD3/CD7) entering late-stage trials
🔹 Expansion into rare cancers, refractory tumors, and even non-oncology diseases
🔹 Ongoing payload and linker innovation, including DXd-based payloads and peptide linkers

👉 Read our full article for a deep dive into H1 2025 ADC sales performance and the Phase III pipeline shaping the future of targeted therapies: https://www.biochempeg.com/article/447.html

09/16/2025

💡 Biomimetic Nanoparticles to Combat Intracellular Bacteria

Researchers at Kumamoto University developed silver-loaded poly(lactic-co-glycolic) nanoparticles (Ag-P NPs), surface-modified with polyethyleneimine (Ag-PP NPs) and fused with Salmonella Typhimurium membrane vesicles (MVs) to form Ag-PP@MV NPs.
🔬 The MV modification enhanced cellular uptake by macrophages and achieved an ~20% reduction of intracellular S. Typhimurium, while maintaining sustained Ag⁺ release. This demonstrates the potential of MV-coated nanoparticles for treating persistent intracellular bacterial infections
😄 Proud to note that SH-PEG-COOH (5000 Da) used in this study was purchased from Biopharma PEG Scientific Inc. (Watertown, MA, USA).
📖 Read more: https://doi.org/10.3390/ma18153470
👉 SH-PEG-COOH 5K: https://www.biochempeg.com/product/SH-PEG-COOH.html

Salmonella enterica serovar Typhimurium (S. Typhimurium) is an intracellular pathogen capable of surviving and replicating within macrophages, which causes foodborne diseases such as gastroenteritis. To develop a strategy against intracellular bacteria in macrophages, we designed silver-loaded biode...

09/11/2025

PEG Linkers in Antibody-Drug Conjugates (ADCs)

To date, 19 ADCs have been approved worldwide, and 3 of them employ PEG linkers to improve stability, solubility, and delivery:

◇ Trodelvy® (Sacituzumab govitecan) – PEGylated cleavable linker
◇ Zynlonta® (Loncastuximab tesirine) – PEG8 spacer in the linker
◇ Jiataile® (Sacituzumab tirumotecan, China) – CL2A linker incorporating PEG8

PEG linkers play a critical role in ADC design by enhancing pharmacokinetics, reducing aggregation, and enabling higher DARs.

At Biopharma PEG, we provide high-purity PEG linkers (impurities

08/18/2025

🚀 PROTAC Therapies: From Concept to Late-Stage Clinical Reality

Proteolysis-targeting chimeras (PROTACs) are transforming the drug development landscape. While no PROTAC-based therapies have yet reached the market, the field is rapidly advancing:

🔬 40+ PROTAC drug candidates are now in clinical trials.
🎯 Targets include AR, ER, BTK, and IRAK4.
🩺 Applications span hematological cancers, solid tumors, and autoimmune disorders.

Notably, three PROTACs have advanced to Phase 3 trials:

√ ARV-471 (Vepdegestrant) – Arvinas/Pfizer (ER degrader) → NDA accepted by FDA, PDUFA: June 5, 2026
√ BMS-986365 – Bristol Myers Squibb (AR degrader)
√ BGB-16673 – BeiGene (BTK degrader)

🌟 With multiple late-stage programs and broad therapeutic potential, PROTACs are on the brink of becoming a new drug class in modern medicine.

👉 Do you think the first FDA-approved PROTAC will arrive by 2026?
https://www.biochempeg.com/article/434.html

07/30/2025

🔹 Y-shape-PEG-NHS, also known as 2-Arm PEG-NHS, this branched PEG derivative features NHS esters at the end of each arm—perfect for efficient, targeted conjugation to amine groups on proteins, peptides, or other biomolecules.
Its unique Y-shaped design enables:
✅ Strong, stable amide bond formation
✅ Enhanced crosslinking for hydrogel networks
✅ Applications in tissue engineering & controlled drug release
At Biopharma PEG, we provide high-purity PEG derivatives—from lab-scale to commercial batches—designed to support your R&D success.
📩 Let’s talk: sales@biochempeg.com

07/15/2025

🚀 New on our blog
Bristol Myers Squibb disclosed the structure of BMS-986238, a second-generation macrocyclic PD-L1 inhibitor.

This novel candidate showcases how strategic molecular engineering—powered by PEG technology—can unlock oral potential in peptide drugs.

🔍 Key features of BMS-986238:

• C18 fatty acid chain boosts albumin binding → significantly longer half-life
• PEG linker acts as a flexible spacer → maintains PD-L1 binding, adds solubility
• Optimized design enables both weekly subcutaneous injection and daily oral dosing

🧪 The molecule recently completed Phase 1 (NCT0668458), demonstrating strong systemic exposure and PD-L1 affinity—without relying on traditional antibodies.

At Biopharma PEG, we’re proud to support the innovation behind such molecules with:
✔️ Monodispersed and Polydispersed GMP-grade PEGs
✔️ Custom PEG linkers tailored to peptide and small molecule drug delivery
✔️ Scalable supply from mg to 100 kg

💡 Whether you're extending half-life or improving oral bioavailability, our PEG solutions help drive the next wave of therapeutic breakthroughs.

📎 Learn more: https://www.biochempeg.com/article/441.html
📩 Contact: sales@biochempeg.com

07/08/2025

🚀 Featured PEGs at Biopharma PEG!

Looking for high-purity monodispersed or polydispersed PEGs for your next project?

Whether you need grams for R&D or 100+ kilograms for GMP production, we've got your supply chain covered.

🔬 Explore our full PEG lineup: https://www.biochempeg.com/
📧 Contact us: sales@biochempeg.com

06/24/2025

HER3-DXd is out—but HER3-targeted cancer therapy is moving forward.

At ASCO 2025:
✅ Zenocutuzumab approved for NRG1+ NSCLC
✅ BL-B01D1 shows 69.2% ORR in tough NSCLC cases
✅ DB-1310 shows promise in EGFR-mutant NSCLC

The future may belong to bispecifics and ADC combos.

Patritumab deruxtecan (HER3-DXd) withdrawal marks a setback in NSCLC. Learn about successful HER3 strategies like Zenocutuzumab and promising bispecific ADCs.

06/13/2025

🎉 Big News from Biopharma PEG!
We’re thrilled to announce that our self-developed Hydrazide-PEG-Hydrazide (HZ-PEG-HZ, 1K) has officially received Drug Master File (DMF) approval from the U.S. FDA!
📄 DMF No.: 041864

This achievement reflects our strong R&D capabilities and unwavering commitment to delivering high-purity, GMP-grade PEG derivatives that meet the rigorous demands of global pharmaceutical development.
📌 GMP-grade available
📌 Scalable supply from milligrams to 100 kilograms
With this regulatory milestone, Biopharma PEG remains a trusted partner for companies developing advanced biologics, ADCs, and targeted drug delivery systems.
🔗 Learn more: https://www.biochempeg.com/article/438.html

06/11/2025

🔬 PROTAC Degraders in Clinical Trials: 2025 Update
PROTACs (Proteolysis Targeting Chimeras) continue to push the boundaries of targeted protein degradation in drug development. In 2025, three leading candidates—ARV-471, BMS-986365, and BGB-16673—have advanced to Phase III clinical trials, marking major milestones for this novel therapeutic class.

✨ Highlights:
✅ ARV-471 (Arvinas/Pfizer): First oral PROTAC in Phase III, targeting ER in advanced breast cancer.
✅ BMS-986365 (Bristol Myers Squibb): A powerful AR degrader showing strong efficacy in mCRPC.
✅ BGB-16673 (BeiGene): First BTK-targeting PROTAC in Phase III for relapsed/refractory CLL and other B-cell malignancies.

These programs show the potential of PROTACs to overcome drug resistance and tackle previously "undruggable" targets.

Read the full 2025 update on PROTAC drug candidates and their clinical progress 👉https://www.biochempeg.com/article/434.html

05/06/2025

🔬 Dual-Payload ADCs: The Future of Cancer Therapy
Dual-payload antibody-drug conjugates (ADCs) are reshaping oncology by combining two powerful payloads in one targeted therapy—boosting efficacy, overcoming drug resistance, and reducing toxicity.

💥 First dual-payload ADC KH815 enters clinical trials.
🧪 14 new candidates revealed at hashtag .
🚀 A game-changer in precision cancer treatment.

👉 Read more: Dual-Payload ADCs: A Revolutionary Leap in Targeted Cancer Therapy https://www.biochempeg.com/article/432.html

Learn about dual-payload ADCs: their introduction, advantages, and the latest research including KH815. Discover the challenges and future of this cancer therapy.